W. Schumacher

发表

Prediction of the therapeutic index of marketed anti-coagulants and anti-platelet agents by guinea pig models of thrombosis and hemostasis.

D. Seiffert, N. Allegretto, P. Wong, 2008, Thrombosis research.

Biomarker Optimization to Track the Antithrombotic and Hemostatic Effects of Clopidogrel in Rats

R. Rehfuss, P. Wong, M. Ogletree, 2007, Journal of Pharmacology and Experimental Therapeutics.

Platelet Aggregometry and Receptor Binding to Predict the Magnitude of Antithrombotic and Bleeding Time Effects of Clopidogrel in Rabbits

R. Rehfuss, P. Wong, M. Ogletree, 2007, Journal of cardiovascular pharmacology.

Murine model of ferric chloride‐induced vena cava thrombosis: evidence for effect of potato carboxypeptidase inhibitor

M. Ogletree, P. Smith, W. Schumacher, 2006, Journal of thrombosis and haemostasis : JTH.

A small-molecule factor XIa inhibitor produces antithrombotic efficacy with minimal bleeding time prolongation in rabbits

P. Wong, W. Schumacher, E. Crain, 2011, Journal of Thrombosis and Thrombolysis.

Inhibition of Factor XIa as a New Approach to Anticoagulation

D. Seiffert, J. Luettgen, M. Quan, 2010, Arteriosclerosis, thrombosis, and vascular biology.

Leukotrienes cause mesenteric vasoconstriction and hemoconcentration in rats without activating thromboxane receptors.

M. Ogletree, W. Schumacher, C. Heran, 1989, Prostaglandins.

Antithrombotic and hemostatic effects of a small molecule factor XIa inhibitor in rats.

E. Liu, M. Ogletree, W. Schumacher, 2007, European journal of pharmacology.

Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding

J. Guay, D. Seiffert, M. Bouvier, 2017, Science Translational Medicine.

Retro-binding thrombin active site inhibitors: identification of an orally active inhibitor of thrombin catalytic activity.

James Lin, E. Iwanowicz, S. D. Kimball, 2002, Bioorganic & medicinal chemistry letters.

Thrombin active site inhibitors: chemical synthesis, in vitro and in vivo pharmacological profile of a novel and selective agent BMS-189090 and analogues.

S. D. Kimball, J. Das, M. Ogletree, 2002, Bioorganic & medicinal chemistry letters.

Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577.

J. Yanchunas, K. Kish, H. Klei, 2009, Bioorganic & medicinal chemistry letters.

Biological maturation and β-adrenergic effectors: development of β-adrenergic receptors in rabbit heart

B. Mirkin, J. Sheppard, W. Schumacher, 2004, Molecular and Cellular Biochemistry.

Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro

P. Wong, J. Luettgen, W. Schumacher, 2009, Thrombosis and Haemostasis.

The combined antiischemic effects of the thromboxane receptor antagonist SQ 30,741 and tissue-type plasminogen activator.

G. Grover, W. Schumacher, C. Parham, 1991, American heart journal.

Platelet‐Activating Factor and the Release of a Platelet‐Derived Coronary Artery Vasodilator Substance in the Canine

S. Kunkel, B. Lucchesi, W. Schumacher, 1986, Circulation research.

Identification of 1-{2-[4-chloro-1'-(2,2-dimethylpropyl)-7-hydroxy-1,2-dihydrospiro[indole-3,4'-piperidine]-1-yl]phenyl}-3-{5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl}urea, a potent, efficacious and orally bioavailable P2Y(1) antagonist as an antiplatelet agent.

P. Lam, Hong Shen, A. Mathur, 2014, Bioorganic & medicinal chemistry letters.

Discovery of diarylurea P2Y(1) antagonists with improved aqueous solubility.

P. Lam, R. Rehfuss, D. Seiffert, 2013, Bioorganic & medicinal chemistry letters.

Discovery of 2-(phenoxypyridine)-3-phenylureas as small molecule P2Y1 antagonists.

J. Y. Roberge, D. Schnur, A. Cacace, 2013, Journal of medicinal chemistry.

Effects of plasma kallikrein deficiency on haemostasis and thrombosis in mice: Murine Ortholog of the Fletcher Trait

D. Seiffert, J. Revelli, Xinkang Wang, 2012, Thrombosis and Haemostasis.

In vitro, antithrombotic and bleeding time studies of BMS-654457, a small-molecule, reversible and direct inhibitor of factor XIa

D. Seiffert, A. Rendina, M. Harpel, 2015, Journal of Thrombosis and Thrombolysis.

Augmentation of Streptokinase‐Induced Thrombolysis by Heparin and Prostacyclin

B. Lucchesi, W. Schumacher, E. Lee, 1985, Journal of cardiovascular pharmacology.

Effect of the Direct Factor Xa Inhibitor Apixaban in Rat Models of Thrombosis and Hemostasis

B. Xin, P. Wong, W. Schumacher, 2010, Journal of cardiovascular pharmacology.

Pharmacological profile of BMS 180,291: a potent, long-acting, orally active thromboxane A2/prostaglandin endoperoxide receptor antagonist.

M. Webb, R. Misra, M. Ogletree, 1993, The Journal of pharmacology and experimental therapeutics.

Thromboxane Receptor Antagonist BMS‐180291, but Not Aspirin, Reduces the Severity of Pacing‐Induced Ischemia in Dogs

G. Grover, M. Ogletree, W. Schumacher, 1994, Journal of cardiovascular pharmacology.

Thrombin inhibition compared with other antithrombotic drugs in rats.

S. Durham, M. Giancarli, J. E. Bird, 1992, Thrombosis research.

Inhibition of tumor necrosis factor-alpha-converting enzyme by a selective antagonist protects brain from focal ischemic injury in rats.

G. Feuerstein, R. Taub, C. Decicco, 2004, Molecular pharmacology.

Effect of Thromboxane Antagonism on Recanalization During Streptokinase-Induced Thrombolysis in Anesthetized Monkeys

W. Schumacher, C. Heran, Christopher L. Heran, 1989, Journal of cardiovascular pharmacology.

Sensitivity of experimental venous and arterial thrombosis and bleeding to ancrod-induced defibrinogenation.

W. Schumacher, T. Steinbacher, C. Heran, 1996, Thrombosis research.

Streptokinase thrombolysis in experimental coronary artery thrombosis: pattern of reflow and effect of a stenosis.

A. Buda, B. Lucchesi, W. Schumacher, 1984, International journal of cardiology.

Conformationally constrained ortho-anilino diaryl ureas: discovery of 1-(2-(1'-neopentylspiro[indoline-3,4'-piperidine]-1-yl)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea, a potent, selective, and bioavailable P2Y1 antagonist.

Steven A. Spronk, P. Lam, D. Schnur, 2013, Journal of medicinal chemistry.

A platelet target for venous thrombosis? P2Y1 deletion or antagonism protects mice from vena cava thrombosis

Christine S. Huang, Xinkang Wang, J. E. Bird, 2012, Journal of Thrombosis and Thrombolysis.

Discovery of nonbenzamidine factor VIIa inhibitors using a biaryl acid scaffold.

D. Cheney, S. Sheriff, E. Liu, 2013, Bioorganic & medicinal chemistry letters.

hc'~_"- ,lr.~mboxane Receptor myoczAial Infarct Size in Monkeys When Given During Reperfusion At a Threshold Dose for !Lnp_rDving Reflow During Thrombolysis .

G. Grover, W. Schumacher, 2016 .

The thromboxane receptor antagonist SQ 30,741 reduces myocardial infarct size in monkeys when given during reperfusion at a threshold dose for improving reflow during thrombolysis.

G. Grover, W. Schumacher, 1990, Journal of the American College of Cardiology.

Quantification of platelet composition in experimental venous thrombosis by real-time polymerase chain reaction.

T. Monticello, Xinkang Wang, W. Schumacher, 2007, Thrombosis research.

The anaphylatoxins C3a and C5a are vasodilators in the canine coronary vasculaturein vitro andin vivo

B. Lucchesi, J. Fantone, R. Webb, 1991, Agents and Actions.

Platelet depletion in experimental myocardial infarction

S. Kunkel, B. Lucchesi, S. Jolly, 1985, Basic Research in Cardiology.

Effect of the thromboxane synthetase inhibitor UK-37,248 (dazoxiben) upon platelet aggregation, coronary artery thrombosis and vascular reactivity.

B. Lucchesi, W. Schumacher, 1983, The Journal of pharmacology and experimental therapeutics.

Effect of the thromboxane A2 receptor antagonist SQ 30,741 on ultimate myocardial infarct size, reperfusion injury and coronary flow reserve.

G. Grover, W. Schumacher, 1989, The Journal of pharmacology and experimental therapeutics.

Role of thromboxane receptor activation in the bronchospastic response to endothelin.

M. Ogletree, W. Schumacher, T. Steinbacher, 1990, Prostaglandins.

Clopidogrel versus prasugrel in rabbits

R. Rehfuss, P. Wong, W. Schumacher, 2008, Thrombosis and Haemostasis.

Magnitude of thromboxane receptor antagonism necessary for antithrombotic activity in monkeys.

M. Ogletree, D. Harris, W. Schumacher, 1989, The American journal of physiology.

The cardioprotective effects of the thromboxane receptor antagonist SQ 30,741 are not reversed by aspirin

G. Grover, W. Schumacher, C. Parham, 1991, Basic Research in Cardiology.

Biphenyl Acid Derivatives as APJ Receptor Agonists.

Michael A. Galella, P. Gargalovic, D. Gordon, 2019, Journal of medicinal chemistry.

Effect of a novel thrombin active-site inhibitor on arterial and venous thrombosis.

W. Schumacher, S. Seiler, N. Balasubramanian, 1994, European journal of pharmacology.

Effects of factor IX or factor XI deficiency on ferric chloride‐induced carotid artery occlusion in mice

G. Feuerstein, D. Seiffert, L. Xu, 2005, Journal of thrombosis and haemostasis : JTH.

Comparison of thrombin active site and exosite inhibitors and heparin in experimental models of arterial and venous thrombosis and bleeding.

M. Ogletree, W. Schumacher, T. Steinbacher, 1993, The Journal of pharmacology and experimental therapeutics.

Effects of Antithrombotic Drugs in a Rat Model of Aspirin-Insensitive Arterial Thrombosis

S. Durham, W. Schumacher, T. Steinbacher, 1993, Thrombosis and Haemostasis.

Active site-directed synthetic thrombin inhibitors: synthesis, in vitro and in vivo activity profile of BMY 44621 and analogs. An examination of the role of the amino group in the D-Phe-Pro-Arg-H series.

N. Meanwell, W. Schumacher, J. J. Wright, 1993, Journal of Medicinal Chemistry.

Effect of thromboxane receptor antagonists on venous thrombosis in rats.

W. Schumacher, C. Heran, 1989, Journal of Pharmacology and Experimental Therapeutics.

Cyanoguanidine-based lactam derivatives as a novel class of orally bioavailable factor Xa inhibitors.

S. Chong, J. Yanchunas, K. Kish, 2009, Bioorganic & medicinal chemistry letters.

Ketene aminal-based lactam derivatives as a novel class of orally active FXa inhibitors.

E. Liu, P. Stein, A. Rendina, 2005, Bioorganic & medicinal chemistry letters.

Arylsulfonamidopiperidone derivatives as a novel class of factor Xa inhibitors.

Ying Wang, Doree Sitkoff, Jing Zhang, 2011, Bioorganic & medicinal chemistry letters.

Low-molecular-weight heparin (fragmin) and thrombin active-site inhibitor (argatroban) compared in experimental arterial and venous thrombosis and bleeding time.

W. Schumacher, T. Steinbacher, C. Heran, 1996, Journal of cardiovascular pharmacology.

Molecular design and structure--activity relationships leading to the potent, selective, and orally active thrombin active site inhibitor BMS-189664.

R. Moquin, James Lin, E. Iwanowicz, 2002, Bioorganic & medicinal chemistry letters.

A ferret model of electrical-induction of arterial thrombosis that is sensitive to aspirin.

S. Durham, W. Schumacher, T. Steinbacher, 1996, Journal of pharmacological and toxicological methods.

Synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors.

G. Bisacchi, W. Meng, R. Zahler, 2002, Bioorganic & medicinal chemistry letters.

Thromboxane receptor antagonist BMS-180291: A new pre-clinical lead

J. Barrish, P. Sprague, R. Morrison, 1992 .

Synthesis of potent and highly selective inhibitors of human tryptase.

G. Bisacchi, W. Meng, R. Zahler, 2002, Bioorganic & medicinal chemistry letters.

Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis

E. Bird, J. Tamasi, Xinkang Wang, 2007, Journal of Thrombosis and Thrombolysis.

Antiplatelet activity of the long-acting thromboxane receptor antagonist BMS 180,291 in monkeys.

M. Ogletree, W. Schumacher, T. Steinbacher, 1992, Prostaglandins.

Inhibition of Tumor Necrosis Factor-α-Converting Enzyme by a Selective Antagonist Protects Brain from Focal Ischemic Injury in Rats

Lin Xu, G. Feuerstein, R. Taub, 2004 .

Bleeding response induced by anti-thrombotic doses of a phosphoinositide 3-kinase (PI3K)-β inhibitor in mice.

P. Shipkova, J. E. Bird, W. Schumacher, 2011, Thrombosis research.

Effect of the Thromboxane Receptor Antagonist SQ 29,548 on Myocardial Infarct Size in Dogs

G. Grover, W. Schumacher, 1988, Journal of cardiovascular pharmacology.

The effect of the thromboxane A2 receptor antagonist SQ 29,548 on the severity of pacing-induced ischemia

G. Grover, W. Schumacher, 2005, Basic Research in Cardiology.

Role of thromboxane receptors in Forssman shock in guinea pigs.

M. Ogletree, W. Schumacher, T. Steinbacher, 1989, Journal of applied physiology.

Effect of thromboxane receptor antagonists on renal artery thrombosis in the cynomolgus monkey.

M. Ogletree, D. Harris, W. Schumacher, 1987, Journal of Pharmacology and Experimental Therapeutics.

Effect of the thromboxane A2-receptor antagonists, SQ 29,548 and SQ 28,668, on the pulmonary hypertensive response to endotoxemia in swine.

M. Ogletree, W. Schumacher, H. Adams, 1987, Pharmacology.

Is exogenous tissue plasminogen activator necessary for antithrombotic efficacy of an inhibitor of thrombin activatable fibrinolysis inhibitor (TAFI) in rats?

E. Bird, J. Tamasi, J. Feyen, 2007, Thrombosis research.

Effect of diltiazem on experimental coronary artery thrombosis in dogs.

B. Lucchesi, W. Schumacher, 1990, Pharmacology.

Effects of factor XI deficiency on ferric chloride‐induced vena cava thrombosis in mice

D. Seiffert, D. Gailani, M. Ogletree, 2006, Journal of thrombosis and haemostasis : JTH.

Evaluation of the Effect of Dopamine and Other Catecholamines on the Electrocardiogram and Blood Pressure of Rats by Means of On‐line Biosignal Processing

W. Schumacher, R. Budden, U. G. Kühl, 1980, Journal of cardiovascular pharmacology.

Development and Time Course of Blood Brain Barrier Disturbances Caused by Hypoxia

W. Gobiet, W. Schumacher, L. Piaszek, 1975 .

Identification of 6-Hydroxypyrimidin-4(1H)-one-3-carboxamides as Potent and Orally Active APJ Receptor Agonists.

P. Gargalovic, D. Gordon, R. Wexler, 2021, ACS medicinal chemistry letters.

The alpha adrenergic response of Down's syndrome platelets.

J. White, G. Schultz, K. Jakobs, 1983, The Journal of pharmacology and experimental therapeutics.

4‐Benzothiazole‐7‐hydroxyindolinyl Diaryl Ureas Are Potent P2Y1 Antagonists with Favorable Pharmacokinetics: Low Clearance and Small Volume of Distribution

Steven A. Spronk, P. Lam, Hong Shen, 2014, ChemMedChem.

Biological maturation and beta-adrenergic effectors: pre- and postnatal development of the adenylate cyclase system in the rabbit heart.

B. Mirkin, J. Sheppard, W. Schumacher, 1982, The Journal of pharmacology and experimental therapeutics.

Does plexin-B1, a semaphorin 4D receptor, play a role in thrombosis?

E. Bird, D. Seiffert, W. Schumacher, 2013, Thrombosis research.

Identification of a Hydroxypyrimidinone Compound (21) as a Potent APJ Receptor Agonist for the Potential Treatment of Heart Failure.

P. Gargalovic, R. Wexler, Tao Wang, 2021, Journal of medicinal chemistry.

Discovery of a Hydroxypyridinone APJ Receptor Agonist as a Clinical Candidate.

Michael A. Galella, P. Gargalovic, Soong-Hoon Kim, 2021, Journal of medicinal chemistry.

Protamine-induced pulmonary hypertension in heparinized monkeys and pigs is inhibited by the thromboxane receptor antagonist SQ 30,741.

M. Ogletree, W. Schumacher, C. Heran, 1990, Eicosanoids.

Design, structure-activity relationships, X-ray crystal structure, and energetic contributions of a critical P1 pharmacophore: 3-chloroindole-7-yl-based factor Xa inhibitors.

Jing Zhang, Doree Sitkoff, Kevin Kish, 2008, Journal of medicinal chemistry.

Inhibition of Factor XIa as a New Approach to Anticoagulation

D. Seiffert, J. Luettgen, M. Quan, 2010, Arteriosclerosis, thrombosis, and vascular biology.

Experimental Coronary Artery Thrombosis in the Absence of Thromboxane A2 Synthesis: Evidence for Alternate Pathways for Coronary Thrombosis

B. Lucchesi, S. Jolly, B. Hook, 1985, Journal of cardiovascular pharmacology.